<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02081001</url>
  </required_header>
  <id_info>
    <org_study_id>XSGO-201</org_study_id>
    <secondary_id>4R44DK096706-02</secondary_id>
    <nct_id>NCT02081001</nct_id>
  </id_info>
  <brief_title>PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients</brief_title>
  <official_title>Comparison of Pharmacokinetic and Pharmacodynamic Profiles of G-Pump™ (Glucagon Infusion) vs. GlucaGen® Delivered Subcutaneously to Subjects With Type 1 Diabetes (T1DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emissary International LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xeris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety, speed of absorption, and onset of action of
      G-Pump™ (glucagon infusion) at three subcutaneous doses as compared to Novo GlucaGen®, all
      delivered via an OmniPod® infusion pump to patients with type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Reach 50% of Maximum Glucose Concentration (Glucose T50%-Early)</measure>
    <time_frame>0 to 150 minutes post-dosing</time_frame>
    <description>The onset of action was assessed by determining the time in minutes required to achieve 50% of the maximum plasma concentration of glucose following each dose of glucagon.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach 50% of Maximum Glucagon Concentration (Glucagon T50%-Early)</measure>
    <time_frame>0 to 150 minutes post-dosing</time_frame>
    <description>The speed of absorption was assessed by determining the time in minutes required to achieve 50% of the maximum plasma concentration of glucagon following each dose of glucagon.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucagon Cmax</measure>
    <time_frame>From 0 to 150 minutes post-dosing</time_frame>
    <description>Maximum plasma concentration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Cmax</measure>
    <time_frame>From 0 to 150 minutes post-dosing</time_frame>
    <description>Maximum plasma concentration of glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon Tmax</measure>
    <time_frame>From 0 to 150 minutes post-dosing</time_frame>
    <description>Time to maximum plasma concentration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Tmax</measure>
    <time_frame>From 0 to 150 minutes post-dosing</time_frame>
    <description>Time to maximum plasma concentration of glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon AUC</measure>
    <time_frame>From 0 to 150 minutes post-dosing</time_frame>
    <description>Area under the plasma concentration time curve for glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose AUC</measure>
    <time_frame>From 0 to 150 minutes post-dosing</time_frame>
    <description>Area under the plasma concentration time curve for glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion Site Discomfort Score at 10 Minutes</measure>
    <time_frame>At 10 minutes post-dosing</time_frame>
    <description>Infusion site discomfort was assessed by the subjects using a 100 mm Visual Analog Scale (VAS) questionnaire at 10 minutes following the initiation of dosing. Subjects were asked to draw a vertical line across the horizontal scale to indicate their current level of discomfort from 0 = no discomfort to 100 = worst possible discomfort. The distance in mm from the left hand anchor to the the first point where the subject's mark crossed the horizontal scale was measured and reported as the infusion site discomfort score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion Site Discomfort Score at 30 Minutes</measure>
    <time_frame>At 30 minutes post-dosing</time_frame>
    <description>Infusion site discomfort was assessed by the subject using a 100 mm Visual Analog Scale (VAS) questionnaire at 30 minutes following the initiation of dosing. Subjects were asked to draw a vertical line across the horizontal scale to indicate their current level of discomfort from 0 = no discomfort to 100 = worst possible discomfort. The distance in mm from the left hand anchor to the the first point where the subject's mark crossed the horizontal scale was measured and reported as the infusion site discomfort score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>G-Pump™ (glucagon infusion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-Pump™ (glucagon infusion); single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Novo Nordisk GlucaGen®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Novo Nordisk GlucaGen®; single subcutaneous infusion doses 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Novo Nordisk GlucaGen®</intervention_name>
    <description>single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg</description>
    <arm_group_label>G-Pump™ (glucagon infusion)</arm_group_label>
    <arm_group_label>Novo Nordisk GlucaGen®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-Pump™ (glucagon infusion)</intervention_name>
    <description>single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg</description>
    <arm_group_label>G-Pump™ (glucagon infusion)</arm_group_label>
    <arm_group_label>Novo Nordisk GlucaGen®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females diagnosed with type 1 diabetes mellitus for at least 24 months

          -  Current usage of subcutaneous insulin pump treatment

          -  Age 18-65 years

          -  C-peptide level &lt; 0.5 ng/ml

          -  Willingness to follow all study procedures, including attending all clinic visits

          -  Subject has provided informed consent and has signed and dated an informed consent
             form before any trial-related activities

        Exclusion Criteria:

          -  Pregnant and/ or Lactating: For women of childbearing potential: there is a
             requirement for a negative urine pregnancy test and for agreement to use contraception
             during the study and for at least 1 month after participating in the study.

          -  HbA1c &gt;10.0%

          -  Renal insufficiency (serum creatinine of 1.2 mg/dL or greater)

          -  Serum ALT or AST equal to or greater than 3 times the upper limit of normal; hepatic
             synthetic insufficiency as defined as a serum albumin of less than 3.0 g/dL; or serum
             bilirubin of over 2.0.

          -  Hematocrit of less than or equal to 34%

          -  Congestive heart failure, NYHA class II, III or IV

          -  History of coronary artery disease

          -  Active foot ulceration

          -  History of a cerebrovascular accident

          -  Active alcohol abuse or substance abuse

          -  Active malignancy, except basal cell or squamous cell skin cancers

          -  Major surgical operation within 30 days prior to screening

          -  Seizure disorder

          -  Current administration of oral or parenteral corticosteroids

          -  Use of an investigational drug within 30 days prior to screening

          -  Bleeding disorder, treatment with warfarin, or platelet count below 50,000

          -  Proliferative or severe non-proliferative retinopathy

          -  Gastroparesis

          -  Personal or family history of pheochromocytoma or disorder with increased risk of
             pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease)

          -  Insulinoma

          -  Allergies to glucagon or glucagon-like products, or any history of significant
             hypersensitivity to glucagon or any related products.

          -  Glycogen storage disease

          -  Any concurrent illness, other than diabetes, that is not controlled by a stable
             therapeutic regimen

          -  Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening.

          -  Any reason the principal investigator deems exclusionary
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Castle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2014</study_first_posted>
  <results_first_submitted>May 13, 2016</results_first_submitted>
  <results_first_submitted_qc>June 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 1, 2016</results_first_posted>
  <last_update_submitted>March 10, 2018</last_update_submitted>
  <last_update_submitted_qc>March 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoglycemia</keyword>
  <keyword>Glucagon</keyword>
  <keyword>Artificial Pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 19 adults ages 18-65 years with type 1 diabetes were recruited over a period of 4 months to receive treatment at a public university hospital.</recruitment_details>
      <pre_assignment_details>A total of 30 subjects were screened for study inclusion. The 19 subjects who met all eligibility criteria were randomized and assigned to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dose Order: 0.3, 1.2 &amp; 2 μg/kg; Drug Order: G-Pump/GlucaGen</title>
          <description>Subjects received three doses of glucagon 2.5 hours apart at each of two treatment visits separated by a wash-out period of 3-28 days. Bolus doses were administered subcutaneously via an OmniPod infusion pump placed on the anterior abdomen. Subjects in this group received doses in the order of 0.3, 1.2 and 2.0 μg/kg of body weight at each visit, and received G-Pump glucagon at the first treatment visit and GlucaGen at the second treatment visit.</description>
        </group>
        <group group_id="P2">
          <title>Dose Order: 0.3, 1.2 &amp; 2 μg/kg; Drug Order: GlucaGen/G-Pump</title>
          <description>Subjects received three doses of glucagon 2.5 hours apart at each of two treatment visits separated by a wash-out period of 3-28 days. Bolus doses were administered subcutaneously via an OmniPod infusion pump placed on the anterior abdomen. Subjects in this group received doses in the order of 0.3, 1.2 and 2.0 μg/kg of body weight at each visit, and received GlucaGen at the first treatment visit and G-Pump glucagon at the second treatment visit.</description>
        </group>
        <group group_id="P3">
          <title>Dose Order: 0.3, 2 &amp; 1.2 μg/kg; Drug Order: G-Pump/GlucaGen</title>
          <description>Subjects received three doses of glucagon 2.5 hours apart at each of two treatment visits separated by a wash-out period of 3-28 days. Bolus doses were administered subcutaneously via an OmniPod infusion pump placed on the anterior abdomen. Subjects in this group received doses in the order of 0.3, 2.0 and 1.2 μg/kg of body weight at each visit, and received G-Pump glucagon at the first treatment visit and GlucaGen at the second treatment visit.</description>
        </group>
        <group group_id="P4">
          <title>Dose Order: 0.3, 2 &amp; 1.2 μg/kg; Drug Order: GlucaGen/G-Pump</title>
          <description>Subjects received three doses of glucagon 2.5 hours apart at each of two treatment visits separated by a wash-out period of 3-28 days. Bolus doses were administered subcutaneously via an OmniPod infusion pump placed on the anterior abdomen. Subjects in this group received doses in the order of 0.3, 2.0 and 1.2 μg/kg of body weight at each visit, and received GlucaGen at the first treatment visit and G-Pump glucagon at the second treatment visit.</description>
        </group>
        <group group_id="P5">
          <title>Dose Order: 1.2, 0.3 &amp; 2 μg/kg; Drug Order: G-Pump/GlucaGen</title>
          <description>Subjects received three doses of glucagon 2.5 hours apart at each of two treatment visits separated by a wash-out period of 3-28 days. Bolus doses were administered subcutaneously via an OmniPod infusion pump placed on the anterior abdomen. Subjects in this group received doses in the order of 1.2, 0.3 and 2.0 μg/kg of body weight at each visit, and received G-Pump glucagon at the first treatment visit and GlucaGen at the second treatment visit.</description>
        </group>
        <group group_id="P6">
          <title>Dose Order: 1.2, 0.3 &amp; 2 μg/kg; Drug Order: GlucaGen/G-Pump</title>
          <description>Subjects received three doses of glucagon 2.5 hours apart at each of two treatment visits separated by a wash-out period of 3-28 days. Bolus doses were administered subcutaneously via an OmniPod infusion pump placed on the anterior abdomen. Subjects in this group received doses in the order of 1.2, 0.3 and 2.0 μg/kg of body weight at each visit, and received GlucaGen at the first treatment visit and G-Pump glucagon at the second treatment visit.</description>
        </group>
        <group group_id="P7">
          <title>Dose Order: 1.2, 2 &amp; 0.3 μg/kg; Drug Order: G-Pump/GlucaGen</title>
          <description>Subjects received three doses of glucagon 2.5 hours apart at each of two treatment visits separated by a wash-out period of 3-28 days. Bolus doses were administered subcutaneously via an OmniPod infusion pump placed on the anterior abdomen. Subjects in this group received doses in the order of 1.2, 2 and 0.3 μg/kg of body weight at each visit, and received G-Pump glucagon at the first treatment visit and GlucaGen at the second treatment visit.</description>
        </group>
        <group group_id="P8">
          <title>Dose Order: 1.2, 2 &amp; 0.3 μg/kg; Drug Order: GlucaGen/G-Pump</title>
          <description>Subjects received three doses of glucagon 2.5 hours apart at each of two treatment visits separated by a wash-out period of 3-28 days. Bolus doses were administered subcutaneously via an OmniPod infusion pump placed on the anterior abdomen. Subjects in this group received doses in the order of 1.2, 2 and 0.3 μg/kg of body weight at each visit, and received GlucaGen at the first treatment visit and G-Pump glucagon at the second treatment visit.</description>
        </group>
        <group group_id="P9">
          <title>Dose Order: 2, 0.3 &amp; 1.2 μg/kg; Drug Order: G-Pump/GlucaGen</title>
          <description>Subjects received three doses of glucagon 2.5 hours apart at each of two treatment visits separated by a wash-out period of 3-28 days. Bolus doses were administered subcutaneously via an OmniPod infusion pump placed on the anterior abdomen. Subjects in this group received doses in the order of 2.0, 0.3 and 1.2 μg/kg of body weight at each visit, and received G-Pump glucagon at the first treatment visit and GlucaGen at the second treatment visit.</description>
        </group>
        <group group_id="P10">
          <title>Dose Order: 2, 0.3 &amp; 1.2 μg/kg; Drug Order: GlucaGen/G-Pump</title>
          <description>Subjects received three doses of glucagon 2.5 hours apart at each of two treatment visits separated by a wash-out period of 3-28 days. Bolus doses were administered subcutaneously via an OmniPod infusion pump placed on the anterior abdomen. Subjects in this group received doses in the order of 2.0, 0.3 and 1.2 μg/kg of body weight at each visit, and received GlucaGen at the first treatment visit and G-Pump glucagon at the second treatment visit.</description>
        </group>
        <group group_id="P11">
          <title>Dose Order: 2, 1.2 &amp; 0.3 μg/kg; Drug Order: G-Pump/GlucaGen</title>
          <description>Subjects received three doses of glucagon 2.5 hours apart at each of two treatment visits separated by a wash-out period of 3-28 days. Bolus doses were administered subcutaneously via an OmniPod infusion pump placed on the anterior abdomen. Subjects in this group received doses in the order of 2.0, 1.2 and 0.3 μg/kg of body weight at each visit, and received G-Pump glucagon at the first treatment visit and GlucaGen at the second treatment visit.</description>
        </group>
        <group group_id="P12">
          <title>Dose Order: 2, 1.2 &amp; 0.3 μg/kg; Drug Order: GlucaGen/G-Pump</title>
          <description>Subjects received three doses of glucagon 2.5 hours apart at each of two treatment visits separated by a wash-out period of 3-28 days. Bolus doses were administered subcutaneously via an OmniPod infusion pump placed on the anterior abdomen. Subjects in this group received doses in the order of 2.0, 1.2 and 0.3 μg/kg of body weight at each visit, and received GlucaGen at the first treatment visit and G-Pump glucagon at the second treatment visit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Xeris G-Pump Glucagon First, Followed by GlucaGen</title>
          <description>Subjects who received G-Pump (glucagon infusion) at the first treatment visit and GlucaGen at the second treatment visit.</description>
        </group>
        <group group_id="B2">
          <title>GlucaGen First, Followed by Xeris G-Pump</title>
          <description>Subjects who received GlucaGen at the first treatment visit and G-Pump (glucagon infusion) at the second treatment visit.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" spread="9.54"/>
                    <measurement group_id="B2" value="32.2" spread="8.38"/>
                    <measurement group_id="B3" value="35.3" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach 50% of Maximum Glucose Concentration (Glucose T50%-Early)</title>
        <description>The onset of action was assessed by determining the time in minutes required to achieve 50% of the maximum plasma concentration of glucose following each dose of glucagon.</description>
        <time_frame>0 to 150 minutes post-dosing</time_frame>
        <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis. In addition, subjects with no increase in glucose concentration post-dosing (i.e., maximum concentration was at time zero) were not evaluable for response and consequently were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 μg/kg G-Pump</title>
            <description>0.3 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O2">
            <title>1.2 μg/kg G-Pump</title>
            <description>1.2 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O3">
            <title>2.0 μg/kg G-Pump</title>
            <description>2.0 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O4">
            <title>0.3μg/kg GlucaGen</title>
            <description>0.3 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O5">
            <title>1.2 μg/kg GlucaGen</title>
            <description>1.2 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O6">
            <title>2.0 μg/kg GlucaGen</title>
            <description>2.0 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach 50% of Maximum Glucose Concentration (Glucose T50%-Early)</title>
          <description>The onset of action was assessed by determining the time in minutes required to achieve 50% of the maximum plasma concentration of glucose following each dose of glucagon.</description>
          <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis. In addition, subjects with no increase in glucose concentration post-dosing (i.e., maximum concentration was at time zero) were not evaluable for response and consequently were not included in the analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" spread="8.76"/>
                    <measurement group_id="O2" value="21.9" spread="18.44"/>
                    <measurement group_id="O3" value="21.3" spread="16.52"/>
                    <measurement group_id="O4" value="7.6" spread="9.45"/>
                    <measurement group_id="O5" value="14.5" spread="15.36"/>
                    <measurement group_id="O6" value="22.8" spread="6.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>2.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.19</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>5.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.43</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach 50% of Maximum Glucagon Concentration (Glucagon T50%-Early)</title>
        <description>The speed of absorption was assessed by determining the time in minutes required to achieve 50% of the maximum plasma concentration of glucagon following each dose of glucagon.</description>
        <time_frame>0 to 150 minutes post-dosing</time_frame>
        <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 μg/kg G-Pump</title>
            <description>0.3 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O2">
            <title>1.2 μg/kg G-Pump</title>
            <description>1.2 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O3">
            <title>2.0 μg/kg G-Pump</title>
            <description>2.0 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O4">
            <title>0.3 μg/kg GlucaGen</title>
            <description>0.3 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O5">
            <title>1.2 μg/kg GlucaGen</title>
            <description>1.2 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O6">
            <title>2.0 μg/kg GlucaGen</title>
            <description>2.0 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach 50% of Maximum Glucagon Concentration (Glucagon T50%-Early)</title>
          <description>The speed of absorption was assessed by determining the time in minutes required to achieve 50% of the maximum plasma concentration of glucagon following each dose of glucagon.</description>
          <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="10.51"/>
                    <measurement group_id="O2" value="12.4" spread="5.07"/>
                    <measurement group_id="O3" value="13.9" spread="4.65"/>
                    <measurement group_id="O4" value="7.6" spread="3.51"/>
                    <measurement group_id="O5" value="10.5" spread="4.46"/>
                    <measurement group_id="O6" value="11.0" spread="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>2.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon Cmax</title>
        <description>Maximum plasma concentration of glucagon</description>
        <time_frame>From 0 to 150 minutes post-dosing</time_frame>
        <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 μg/kg G-Pump</title>
            <description>0.3 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O2">
            <title>1.2 μg/kg G-Pump</title>
            <description>1.2 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O3">
            <title>2.0 μg/kg G-Pump</title>
            <description>2.0 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O4">
            <title>0.3 μg/kg GlucaGen</title>
            <description>0.3 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O5">
            <title>1.2 μg/kg GlucaGen</title>
            <description>1.2 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O6">
            <title>2.0 μg/kg GlucaGen</title>
            <description>2.0 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Cmax</title>
          <description>Maximum plasma concentration of glucagon</description>
          <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis.</population>
          <units>pg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.1" spread="57.66"/>
                    <measurement group_id="O2" value="328.2" spread="127.9"/>
                    <measurement group_id="O3" value="440.6" spread="310.9"/>
                    <measurement group_id="O4" value="140.2" spread="53.69"/>
                    <measurement group_id="O5" value="229.3" spread="161.6"/>
                    <measurement group_id="O6" value="446.9" spread="220.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Cmax</title>
        <description>Maximum plasma concentration of glucose</description>
        <time_frame>From 0 to 150 minutes post-dosing</time_frame>
        <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 μg/kg G-Pump</title>
            <description>0.3 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O2">
            <title>1.2 μg/kg G-Pump</title>
            <description>1.2 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O3">
            <title>2.0 μg/kg G-Pump</title>
            <description>2.0 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O4">
            <title>0.3 μg/kg GlucaGen</title>
            <description>0.3 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O5">
            <title>1.2 μg/kg GlucaGen</title>
            <description>1.2 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O6">
            <title>2.0 μg/kg GlucaGen</title>
            <description>2.0 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Cmax</title>
          <description>Maximum plasma concentration of glucose</description>
          <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.6" spread="43.1"/>
                    <measurement group_id="O2" value="198.8" spread="49.37"/>
                    <measurement group_id="O3" value="212.6" spread="57.18"/>
                    <measurement group_id="O4" value="162.0" spread="51.69"/>
                    <measurement group_id="O5" value="183.3" spread="66.15"/>
                    <measurement group_id="O6" value="200.6" spread="63.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon Tmax</title>
        <description>Time to maximum plasma concentration of glucagon</description>
        <time_frame>From 0 to 150 minutes post-dosing</time_frame>
        <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 μg/kg G-Pump</title>
            <description>0.3 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O2">
            <title>1.2 μg/kg G-Pump</title>
            <description>1.2 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O3">
            <title>2.0 μg/kg G-Pump</title>
            <description>2.0 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O4">
            <title>0.3 μg/kg GlucaGen</title>
            <description>0.3 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O5">
            <title>1.2 μg/kg GlucaGen</title>
            <description>1.2 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O6">
            <title>2.0 μg/kg GlucaGen</title>
            <description>2.0 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Tmax</title>
          <description>Time to maximum plasma concentration of glucagon</description>
          <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="23.42"/>
                    <measurement group_id="O2" value="27.3" spread="12.93"/>
                    <measurement group_id="O3" value="31.9" spread="15.93"/>
                    <measurement group_id="O4" value="23.3" spread="10.71"/>
                    <measurement group_id="O5" value="23.9" spread="6.31"/>
                    <measurement group_id="O6" value="23.9" spread="8.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estmate ratio</param_type>
            <param_value>1.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Tmax</title>
        <description>Time to maximum plasma concentration of glucose</description>
        <time_frame>From 0 to 150 minutes post-dosing</time_frame>
        <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis. In addition, subjects with no increase in glucose concentration post-dosing (i.e., maximum concentration was at time zero) were not evaluable for response and consequently were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 μg/kg G-Pump</title>
            <description>0.3 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O2">
            <title>1.2 μg/kg G-Pump</title>
            <description>1.2 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O3">
            <title>2.0 μg/kg G-Pump</title>
            <description>2.0 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O4">
            <title>0.3 μg/kg GlucaGen</title>
            <description>0.3 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O5">
            <title>1.2 μg/kg GlucaGen</title>
            <description>1.2 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O6">
            <title>2.0 μg/kg GlucaGen</title>
            <description>2.0 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Tmax</title>
          <description>Time to maximum plasma concentration of glucose</description>
          <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis. In addition, subjects with no increase in glucose concentration post-dosing (i.e., maximum concentration was at time zero) were not evaluable for response and consequently were not included in the analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" spread="29.62"/>
                    <measurement group_id="O2" value="49.5" spread="41.79"/>
                    <measurement group_id="O3" value="49.4" spread="40.59"/>
                    <measurement group_id="O4" value="25.9" spread="28.38"/>
                    <measurement group_id="O5" value="31.2" spread="34.75"/>
                    <measurement group_id="O6" value="52.8" spread="20.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>2.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.95</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>4.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.49</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>2.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon AUC</title>
        <description>Area under the plasma concentration time curve for glucagon</description>
        <time_frame>From 0 to 150 minutes post-dosing</time_frame>
        <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 μg/kg G-Pump</title>
            <description>0.3 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O2">
            <title>1.2 μg/kg G-Pump</title>
            <description>1.2 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O3">
            <title>2.0 μg/kg G-Pump</title>
            <description>2.0 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O4">
            <title>0.3 μg/kg GlucaGen</title>
            <description>0.3 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O5">
            <title>1.2 μg/kg GlucaGen</title>
            <description>1.2 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O6">
            <title>2.0 μg/kg GlucaGen</title>
            <description>2.0 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon AUC</title>
          <description>Area under the plasma concentration time curve for glucagon</description>
          <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis.</population>
          <units>(pg/dl)*minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12104" spread="3944"/>
                    <measurement group_id="O2" value="21177" spread="6139"/>
                    <measurement group_id="O3" value="27595" spread="14530"/>
                    <measurement group_id="O4" value="11070" spread="3032"/>
                    <measurement group_id="O5" value="15781" spread="7874"/>
                    <measurement group_id="O6" value="27355" spread="10757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose AUC</title>
        <description>Area under the plasma concentration time curve for glucose</description>
        <time_frame>From 0 to 150 minutes post-dosing</time_frame>
        <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 μg/kg G-Pump</title>
            <description>0.3 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O2">
            <title>1.2 μg/kg G-Pump</title>
            <description>1.2 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O3">
            <title>2.0 μg/kg G-Pump</title>
            <description>2.0 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O4">
            <title>0.3 μg/kg GlucaGen</title>
            <description>0.3 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O5">
            <title>1.2 μg/kg GlucaGen</title>
            <description>1.2 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O6">
            <title>2.0 μg/kg GlucaGen</title>
            <description>2.0 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose AUC</title>
          <description>Area under the plasma concentration time curve for glucose</description>
          <population>All randomized, evaluable subjects. Two subjects not evaluable for response to GlucaGen due to dosing errors were excluded from the analysis.</population>
          <units>(mg/dl)*minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22296" spread="7998"/>
                    <measurement group_id="O2" value="26251" spread="7110"/>
                    <measurement group_id="O3" value="27360" spread="8190"/>
                    <measurement group_id="O4" value="21005" spread="7931"/>
                    <measurement group_id="O5" value="24079" spread="9348"/>
                    <measurement group_id="O6" value="25845" spread="8624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Regression, Cox</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infusion Site Discomfort Score at 10 Minutes</title>
        <description>Infusion site discomfort was assessed by the subjects using a 100 mm Visual Analog Scale (VAS) questionnaire at 10 minutes following the initiation of dosing. Subjects were asked to draw a vertical line across the horizontal scale to indicate their current level of discomfort from 0 = no discomfort to 100 = worst possible discomfort. The distance in mm from the left hand anchor to the the first point where the subject's mark crossed the horizontal scale was measured and reported as the infusion site discomfort score.</description>
        <time_frame>At 10 minutes post-dosing</time_frame>
        <population>All treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 μg/kg G-Pump</title>
            <description>0.3 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O2">
            <title>1.2 μg/kg G-Pump</title>
            <description>1.2 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O3">
            <title>2.0 μg/kg G-Pump</title>
            <description>2.0 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O4">
            <title>0.3 μg/kg GlucaGen</title>
            <description>0.3 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O5">
            <title>1.2 μg/kg GlucaGen</title>
            <description>1.2 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O6">
            <title>2.0 μg/kg GlucaGen</title>
            <description>2.0 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Infusion Site Discomfort Score at 10 Minutes</title>
          <description>Infusion site discomfort was assessed by the subjects using a 100 mm Visual Analog Scale (VAS) questionnaire at 10 minutes following the initiation of dosing. Subjects were asked to draw a vertical line across the horizontal scale to indicate their current level of discomfort from 0 = no discomfort to 100 = worst possible discomfort. The distance in mm from the left hand anchor to the the first point where the subject's mark crossed the horizontal scale was measured and reported as the infusion site discomfort score.</description>
          <population>All treated subjects</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="18.9"/>
                    <measurement group_id="O2" value="18.9" spread="21.1"/>
                    <measurement group_id="O3" value="22.7" spread="25.5"/>
                    <measurement group_id="O4" value="2.2" spread="9.2"/>
                    <measurement group_id="O5" value="0.3" spread="1.0"/>
                    <measurement group_id="O6" value="0.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.1</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-19.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.1</ci_lower_limit>
            <ci_upper_limit>-8.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-23.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.0</ci_lower_limit>
            <ci_upper_limit>-12.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infusion Site Discomfort Score at 30 Minutes</title>
        <description>Infusion site discomfort was assessed by the subject using a 100 mm Visual Analog Scale (VAS) questionnaire at 30 minutes following the initiation of dosing. Subjects were asked to draw a vertical line across the horizontal scale to indicate their current level of discomfort from 0 = no discomfort to 100 = worst possible discomfort. The distance in mm from the left hand anchor to the the first point where the subject's mark crossed the horizontal scale was measured and reported as the infusion site discomfort score.</description>
        <time_frame>At 30 minutes post-dosing</time_frame>
        <population>All treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 μg/kg G-Pump</title>
            <description>0.3 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O2">
            <title>1.2 μg/kg G-Pump</title>
            <description>1.2 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O3">
            <title>2.0 μg/kg G-Pump</title>
            <description>2.0 μg/kg dose of G-Pump (glucagon infusion) delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O4">
            <title>0.3 μg/kg GlucaGen</title>
            <description>0.3 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O5">
            <title>1.2 μg/kg GlucaGen</title>
            <description>1.2 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
          <group group_id="O6">
            <title>2.0 μg/kg GlucaGen</title>
            <description>2.0 μg/kg dose of GlucaGen delivered via OmniPod sc infusion pump</description>
          </group>
        </group_list>
        <measure>
          <title>Infusion Site Discomfort Score at 30 Minutes</title>
          <description>Infusion site discomfort was assessed by the subject using a 100 mm Visual Analog Scale (VAS) questionnaire at 30 minutes following the initiation of dosing. Subjects were asked to draw a vertical line across the horizontal scale to indicate their current level of discomfort from 0 = no discomfort to 100 = worst possible discomfort. The distance in mm from the left hand anchor to the the first point where the subject's mark crossed the horizontal scale was measured and reported as the infusion site discomfort score.</description>
          <population>All treated subjects</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="4.8"/>
                    <measurement group_id="O2" value="1.5" spread="4.0"/>
                    <measurement group_id="O3" value="3.8" spread="9.0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0.7" spread="2.6"/>
                    <measurement group_id="O6" value="0.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event information was collected from the time a subject provided written informed consent at the screening visit through the follow-up visit occurring 3-14 days after the final dose of study drug, a total time of 6-10 weeks per subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>G-Pump™ (Glucagon Infusion)</title>
          <description>G-Pump™ (glucagon infusion); single subcutaneous doses of 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg delivered via infusion pump</description>
        </group>
        <group group_id="E2">
          <title>Novo Nordisk GlucaGen®</title>
          <description>Novo Nordisk GlucaGen®; single subcutaneous doses of 0.3 μg/kg, 1.2 μg/kg, and 2.0 μg/kg delivered by infusion pump</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infusion site swelling</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Drug withdrawal headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infusion site bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Catheter site rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Martin J. Cummins, VP for Drug Development</name_or_title>
      <organization>Xeris Pharmaceuticals, Inc.</organization>
      <phone>512-498-2675</phone>
      <email>mcummins@xerispharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

